Profire Energy (PFIE): Triple Digit Growth in the Third Quarter
Profire Energy Inc. (OTCBB:PFIE) is an innovative provider of safe and efficient burner management systems and services for use in oilfield combustion, with customers like Devon Energy Corporation (NYSE: DVN) and EnCana Corporation (NYSE: ECA), as well as smaller “mom and pop” oil and gas exploration and development companies.
Cellceutix Files Investigational New Drug Application with FDA for Novel Cancer Drug
With the hubbub around p53 as a potential breakthrough in cancer research, it is interesting to note that Cellceutix Corporation (OTCBB:CTIX) has submitted its Investigational New Drug application to the FDA. The news was posted on their website after the closing bell on Friday and released nationally this morning.
The Black Market for Diabetic Strips on Ebay - FOX News Baltimore ($ALRT)
The Black Market for diabetic electronic test strips is a growing concern. As reported by several television stations, it is becoming a "business" for many, but contains great risk for diabetics that are turning to those sources for supplies. The video provided in the article is just one of many, but spotlights just how prevalent the problem truly is.
Unilife CEO to purchase up to U.S. $1.0 Million in $UNIS shares
There is a whole community of traders who track and follow insider transactions. Unilife Corporation (NASDAQ:UNIS) has been seeing its fair share of insider buys with CEO Alan Shortall heading the purchases and growing a substantial position. ProActive Newsroom has followed Unilife closely and recently issued an article highlighting the Company.
An excerpt from the article,
Ventrus Biosciences Launches Phase III Trial for Hemorrhoid Therapy
There are no FDA approved treatments for hemorrhoids currently, but Ventrus Biosciences (NASDAQ:VTUS) is aiming to change that fact. It was released yesterday by the Company that enrollment has commenced in Ventrus' pivotal Phase III trial studying VEN309 as a new therapy for hemorrhoids.
Unilife Begins the Supplying of Product to Sanofi - $UNIS
Now settled-in to their new state-of-the-art facilities, Unilife has hit another milestone with the commencement of shipments of the Unifill syringe to Sanofi. This article discusses the next phase of the Unilife/Sanofi contract as well as features Alan Shortall, CEO of Unilife, in a brief video showing the proprietary syringe.
The True Value of a SPA: An Inside Look at CorMedix
With its new Special Protocol Assessment with the U.S. Food and Drug Administration, CorMedix will be conducting Phase III research for Deferiprone as an indication for Contrast-Induced Acute Kidney Injury. Often times, the importance or value of an SPA is overlooked, but it the case of CorMedix, it certainly warrants a closer look.
A portion of the article: